• Passionate about drug development and bringing innovative products to patients • Excel at the interface of science and business, leading strategic partnerships and decision-making in a cross-functional environment. • Strong scientific background with over ten years of biopharmaceutical industry experience in various disease areas

Senior Alliance Manager @ • Currently managing collaborations with universities, start-ups and larger biopharmaceuticals in Asia, EU and US focusing on research and clinical development in oncology, NASH, PAH and RA. • Led the integration team for the Gilead acquisition of EpiTherapeutics. • Manage internal decision process and external governance committees to maintain alignment between Gilead’s strategy and collaborations objectives, optimizing the value derived from each alliance. • Actively participate in the drafting and review of different types of agreements and ensure reporting of financial and non-financial partner obligations. Renegotiate license and collaboration agreement terms as necessary. • Contribute to the drug development strategy on partnered programs as a project team member. • Promote internal awareness of contractual requirements and facilitate the understanding of partners’ perspective to prevent potential issues. From September 2014 to Present (1 year 4 months) Global Project Manager, Portfolio Management & Operations @ Antibody Drug Conjugate oncology project • Integrated project manager assuming end-to-end program management, leading the core, clinical, pharmacology and biomarker teams. • Led molecule strategic development assessment process including indication selection, target product profile, Ph1-Ph3 clinical development plan and market assessment. • Led team through IND filing and clinical protocol development (project currently in Ph1 dose expansion). • Accountable for the project timeline, budget (>$50M) and resource requests. • Collaborating closely with the project team leader to frame and propose investment opportunities to the functional and portfolio review committees. Kadcyla (anti-HER2 Antibody Drug Conjugate) • Managed the pharmacology team during Kadcyla health authorities filing and approval (US, EU, JAPAN, ROW affiliates). Lucentis (Ocular anti-VEGF therapy) • Close interaction with the lifecycle team and external partners to develop long acting ocular delivery solutions. • Managed the pharmacology team during IND filing process and FDA interaction; Managed separate tiger team to develop in-licensed long acting technology. • Collaborate and effectively align a broad range of functions including research, clinical development, portfolio planning, regulatory, finance and global product strategy to lead cross-functional teams throughout Genentech development path, business cycle and review committees. • Strong analytical skills and complex problem solving ability using project and portfolio attributes such as various clinical indications, market size, timelines, PTS, LOE and NPV to frame investment decisions. • Actively contribute and facilitate strategic planning, developing project’s vision and core strategy, indication selection, clinical development plan, product profile and probability of technical success. • Manage risk interdependencies across teams and effectively articulate molecule strategy through clear and timely communication.. From June 2012 to August 2014 (2 years 3 months) Project Manager, Portfolio Management and Operations @ Clinical project management for a large cross-functional team developing new immunotherapy (Anti-PD-L1, MPDL3280A). • Managed the clinical team during Ph1 dose escalation and expansion. • Actively contributed to the accelerated clinical development plan and fast to market strategy. • Partnered with team leader and core team to lead the team through multiple committee reviews. From November 2011 to May 2012 (7 months) Project Manager, Translational Neuroscience @ • Outsourcing liaison between Genentech neuroscience research teams and international CROs (Europe and Asia) for the design, execution and review of complex pre-clinical studies. • Managed outsourcing budget, contracts negotiation and execution. • Deployed new project management software and database for translational research, trained project teams and managed interaction with vendor. From December 2010 to May 2012 (1 year 6 months) Senior Research Associate, Department of Protein Engineering @ • Productive research on the mitotic checkpoint and Wnt pathway resulting in two patents and five publications in top peer-reviewed journals. • Award recipient from the research leadership team at the Genentech 2008 post-doctoral off-site. From July 2009 to December 2010 (1 year 6 months) Research Associate / Ph.D. Student, Department of Protein Engineering. @ Structure-function relationship of the chromosomal passenger complex during mitosis. Focus on crystallography, NMR, biochemistry and cell biology to elucidate the function of proteins required for mitosis (Borealin and Survivin). From February 2005 to June 2009 (4 years 5 months) Intern @ Hepatitis C virus RNA polymerase (NS5b) expression and purification using molecular biology and protein engineering for structural biology studies. From March 2004 to May 2004 (3 months) Intern @ Optimized gene therapy vectors for cftr gene replacement as potential cystic fibrosis therapy. From June 2002 to August 2002 (3 months)

Strategic Decision and Risk Management Professional Certificate, Decision Quality and Analysis @ Stanford University From 2013 to 2015 PhD, Protein Engineering @ Université de Provence (Aix-Marseille I) From 2005 to 2009 Master of Engineering (M.Eng.), Biotechnology @ Ecole Sup. d'Ingenieur de Luminy - Marseille From 2003 to 2005 BS, Biochemistry and Microbiology @ Université de Bretagne Occidentale From 2000 to 2002 Eric Bourhis, Ph.D. is skilled in: Biochemistry, Biotechnology, Molecular Biology, Biopharmaceuticals, Cell Biology, Protein Chemistry, Neuroscience, Project Management, Protein Purification, Pharmaceutical Industry, CRO, Drug Development, Protein Engineering, Oncology, Protein Expression